Abingworth LLP E Ffector Therapeutics, Inc. Call Options Transaction History
Abingworth LLP
- $301 Million
- Q4 2022
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding EFTR
# of Institutions
5Shares Held
6.46MCall Options Held
0Put Options Held
0About eFFECTOR Therapeutics, Inc.
- Ticker EFTR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,452,800
- Description
- eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-sma...